NCT07172282 2026-03-19
INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases
Northwell Health
Phase EARLY_PHASE1 Recruiting
Clinical Trials
11 trialsNCT07193862 2026-02-27
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
Northwell Health
Phase EARLY_PHASE1 Recruiting
NCT05759728 2026-01-13
A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
Carina Biotech Limited
Phase 1/2 Recruiting
NCT06540326 2025-12-22
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06353854 2025-10-06
CORESIM
Federation Francophone de Cancerologie Digestive
Recruiting
NCT06008119 2025-09-18
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Shanghai Kechow Pharma, Inc.
Phase 3 Recruiting
NCT06764680 2025-08-24
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT05248581 2025-07-08
Living Donor Liver Transplant for Unresectable Colorectal Liver Metastases
University of Rochester
Recruiting
NCT07044921 2025-07-01
Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.
Chinese PLA General Hospital
Phase 2 Recruiting
NCT07012954 2025-06-24
ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC
Sun Yat-sen University
Phase 1/2 Recruiting
NCT05727163 2025-05-30
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
Sun Yat-sen University
Phase 2 Recruiting